Wells Fargo Maintains Overweight on WAVE Life Sciences, Raises Price Target to $22

Benzinga · 10/16 17:25
Wells Fargo analyst Tiago Fauth maintains WAVE Life Sciences (NASDAQ:WVE) with a Overweight and raises the price target from $11 to $22.